(AOF) – Inventiva (-2.54% to 3.26 euros) is down after announcing a net loss more than doubled in 2023. The biotech specializing in the treatment of steatohepatitis associated with metabolic dysfunction (NASH) lost 110.42 million euros compared to 54.42 million in 2022, for a turnover of 17.47 million euros, compared to 12.17 million in 2022. Cash and cash equivalents reach 26.9 million euros compared to 86.7 million in 2022, which gives the company financial visibility until the start of the third quarter of 2024.
“Inventiva has achieved many clinical and financial milestones in 2023,” comments CEO Frédéric Cren.
Inventiva highlights that its research and development expenses for the year 2023 showed an increase of 82% compared to 2022. “This increase is mainly linked to the clinical development activities planned and carried out in 2023, partially offset by the payments of initial stages received from the partners CTTQ and Hepalys”, she specifies.
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
